Compared with patients diagnosed with MDS/MPN-RS-T within the Mayo–Moffitt cohort (n = 158), those diagnosed with 2022 WHO-defined MDS/MPN-SF3B1-T in our cohort (training cohort 1, n = 180) had a younger median age (65 versus 71 years), a lower median hemoglobin level (74 versus 95 g/L) and a greater percentage of TET2 mutations (29.5% versus 7.0%, P = 0.003) at diagnosis (Supplementary Table S4) [11]. The gene discussed is TET2; the disease is myeloproliferative disorder.